Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Rowland

Showing results (41-50 of 184) with videos related to

Pageof 19
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Author's ReplyMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
European Journal of Clinical Pharmacology|June 24, 2014
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxinsKyra J Barnes, Andrew Rowland, Thomas M Polasek, et al.
Therapeutic Advances in Drug Safety|October 20, 2015
Pharmacists in Australian general practice: an opportunity for expertise in precision medicineThomas M Polasek, Andrew Rowland, Michael D Wiese, et al.
Frontiers in Oncology|September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and DocetaxelAshley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 26, 2008
The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activitiesAndrew Rowland, Kathleen M Knights, Peter I Mackenzie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
The Oncologist|April 29, 2021
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with AbemaciclibSarah Badaoui, Ganessan Kichenadasse, Andrew Rowland, et al.
Archives of Disease in Childhood|June 10, 2016
Failure to evaluate introduction of female genital mutilation mandatory reportingFelicity Gerry, Andrew Rowland, Sam Fowles, et al.
Pageof 19

Showing results (41-50 of 184) with videos related to

Sort By:
Pageof 19
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Author's ReplyMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
European Journal of Clinical Pharmacology|June 24, 2014
Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxinsKyra J Barnes, Andrew Rowland, Thomas M Polasek, et al.
Therapeutic Advances in Drug Safety|October 20, 2015
Pharmacists in Australian general practice: an opportunity for expertise in precision medicineThomas M Polasek, Andrew Rowland, Michael D Wiese, et al.
Frontiers in Oncology|September 12, 2019
Predictors of Long-Term Disease Control and Survival for HER2-Positive Advanced Breast Cancer Patients Treated With Pertuzumab, Trastuzumab, and DocetaxelAshley M Hopkins, Andrew Rowland, Ross A McKinnon, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 26, 2008
The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activitiesAndrew Rowland, Kathleen M Knights, Peter I Mackenzie, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Response to the Letter to the Editor: Lung Immune Prognostic Index for Outcome Prediction to Immunotherapy in Patients With NSCLCMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
Pigment Cell & Melanoma Research|February 14, 2019
Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial dataAshley M Hopkins, Madele Van Dyk, Andrew Rowland, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 19, 2019
Evaluation of the Lung Immune Prognostic Index for Prediction of Survival and Response in Patients Treated With Atezolizumab for NSCLC: Pooled Analysis of Clinical TrialsMichael J Sorich, Andrew Rowland, Christos S Karapetis, et al.
The Oncologist|April 29, 2021
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with AbemaciclibSarah Badaoui, Ganessan Kichenadasse, Andrew Rowland, et al.
Archives of Disease in Childhood|June 10, 2016
Failure to evaluate introduction of female genital mutilation mandatory reportingFelicity Gerry, Andrew Rowland, Sam Fowles, et al.
Pageof 19